Rheumatology Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which generally leads to disability, progressive joint deformity, and occasionally premature death. RA may affect many tissues and organs, but it principally attacks the joints, producing an inflammatory synovitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. The treatment options available for rheumatoid arthritis are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (biologics).

MARKET DYNAMICS

The Rheumatology Drugs market is driving due to the rise in prevalence of arthritis, increasing acceptance of biopharmaceuticals, and presence of well-defined regulatory guidelines in developed economies. However, the accessibility of the treatment, patent expiration of blockbuster drugs and alternative treatment options for rheumatoid arthritis are projected to hamper the market growth.

MARKET SCOPE

The "Rheumatology Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Rheumatology Drugs market with detailed market segmentation by therapeutic molecule and route of administration. The Rheumatology Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Rheumatology Drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Rheumatology Drugs market is segmented on the basis of therapeutic molecule and route of administration. On the basis of therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. On the basis of route of administration, the market is categorized oral and parenteral..

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Rheumatology Drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Rheumatology Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Rheumatology Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Rheumatology Drugs market in these regions.

Rheumatology Drugs Market Report Analysis

Rheumatology Drugs Market

• 
  CAGR (2023 - 2031)

  XX%
• Market Size 2023
  US$ XX Million
• Market Size 2031
  US$ XX Million

Report Coverage

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope

• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis

• Industry landscape and competition analysis & recent developments
• Detailed company profiles

• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

• AbbVie
• Regeneron Pharmaceuticals, Inc.
• Novartis International AG
• Pfizer Inc.
• Bristol-Myers Squibb.
• Hoffmann-La Roche AG
• Johnson and Johnson
• Boehringer Ingelheim GmbH
• UCB S.A.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

By Therapeutic Molecule

• Pharmaceuticals
• Biopharmaceuticals

By Route of Administration

• Oral
• Parenteral

MARKET PLAYERS

The report covers key developments in the Rheumatology Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Rheumatology Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for Rheumatology Drugs in the global market. Below mentioned is the list of few companies engaged in the Rheumatology Drugs market.

The report also includes the profiles of key players in Rheumatology Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•  AbbVie
  
•  Regeneron Pharmaceuticals, Inc.
  
•  Novartis International AG
  
•  Pfizer Inc.
  
•  Bristol-Myers Squibb.
  
•  Hoffmann-La Roche AG
  
•  Johnson and Johnson
  
•  Boehringer Ingelheim GmbH
  
•  UCB S.A.
  
•  Amgen Inc.
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Rheumatology Drugs Market Report Scope